Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
May 19, 2022 06:00 ET
|
Voyager Therapeutics, Inc.
VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing Data demonstrate...
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting
May 16, 2022 06:00 ET
|
Voyager Therapeutics, Inc.
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid...
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
May 04, 2022 16:01 ET
|
Voyager Therapeutics, Inc.
Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™ AAV9- and AAV5-derived...
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
May 03, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...
Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
March 22, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
March 08, 2022 06:16 ET
|
Voyager Therapeutics, Inc.
License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional...
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
March 08, 2022 01:15 ET
|
Voyager Therapeutics, Inc.
Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties Novartis receives target-specific access to...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
February 10, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...
Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee
February 03, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating officer CAMBRIDGE, Mass., Feb. ...
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
November 19, 2021 07:30 ET
|
Voyager Therapeutics, Inc.
Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS Proprietary...